参考文献/References:
[1] Hilson AJ.Functional renal imaging with nuclear medicine[J].Abdom Imaging, 2003, 28(2):176-179.DOI:10.1007/s00261-001-0184-7.
[2] Sigman EM, Elwood C, Reagan ME, et al.The renal clearance of 131I labelled sodium iothalamate in man[J].Invest Urol, 1965, 2:432-438.
[3] Cohen ML, Smith FG, Mindell RS, et al.A simple, reliable method of measuring glomerular filtration rate using single, low dose Sodium iothalamate I-131[J].Pediatrics, 1969, 43(3):407-415.
[4] Israelit AH, Long DL, White MG, et al.Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 125I-iothalamate[J].Kidney Int, 1973, 4(5):346-349.
[5] Poggio ED, Nef PC, Wang X, et al.Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients[J].Am J Kidney Dis, 2005, 46(2):242-252.DOI:10.1053/j.ajkd.2005.04.023.
[6] Apperloo AJ, De Zeeuw D, Donker AJ, et al.Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran[J].J Am Soc Nephrol, 1996, 7(4):567-572..
[7] Perrone RD, Steinman TI, Beck GJ, et al.Utility of radioisotopic filtration markers in chronic renal insufficiency:simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin.The Modification of Diet in Renal Disease Study[J].Am J Kidney Dis, 1990, 16(3):224-235.
[8] Rahn KH, Heidenreich S, Brückner D.How to assess glomerular function and damage in humans[J].J Hypertens, 1999, 17(3):309-317.
[9] Adefuin PY, Gur A, Siegel NJ, et al.Single subcutaneous injection of iothalamate Sodium 125I to measure glomerular filtration rate[J].JAMA, 1976, 235(14):1467-1469.
[10] Hall PM, Rolin H.Iothalamate clearance and its use in large-scale clinical trials[J].Curr Opin Nephrol Hypertens, 1995, 4(6):510-513.
[11] Bajaj G, Alexander SR, Browne R, et al.125Iodine-iothalamate clearance in children.A simple method to measure glomerular filtration[J].Pediatr Nephrol, 1996, 10(1):25-28.
[12] Wagner D, Kniepeiss D, Stiegler P, et al.The assessment of GFR after orthotopic liver transplantation using cystatin C and creatinine-based equations[J].Transpl Int, 2012, 25(5):527-536.DOI:10.1111/j.1432-2277.2012.01449.x.
[13] Cocchetto DM, Tschanz C, Bjornsson TD.Decreased rate of creatinine production in patients with hepatic disease:implications for estimation of creatinine clearance[J].Ther Drug Monit, 1983, 5(2):161-168.
[14] Hudson JQ, Owens HM, Fleckenstein JF, et al.Performance of methods to assess kidney function in a predominantly overweight sample of patients with liver disease[J].Ren Fail, 2013, 35(2):249-256.DOI:10.3109/0886022X.2012.745786.
[15] Skluzacek PA, Szewc RG, Nolan CR, et al.Prediction of GFR in liver transplant candidates[J].Am J Kidney Dis, 2003, 42(6):1169-1176.
[16] Gonwa TA, Jennings L, Mai ML, et al.Estimation of glomerular filtration rates before and after orthotopic liver transplantation:evaluation of current equations[J].Liver Transpl, 2004, 10(2):301-309.DOI:10.1002/lt.20017.
[17] Filler G, Browne R, Seikaly MG.Glomerular filtration rate as a putative ‘surrogate end-point’ for renal transplant clinical trials in children[J].Pediatr Transplant, 2003, 7(1):18-24.
[18] Seikaly MG, Browne R, Simonds N, et al.Glomerular filtration rate in children following renal transplantation[J].Pediatr Transplant, 1998, 2(3):231-235.
[19] Filler G, Priem F, Lepage N, et al.Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children[J].Clin Chem, 2002, 48(5):729-736.
[20] Booysen HL, Woodiwiss AJ, Raymond A, et al.Chronic kidney disease epidemiology collaboration-derived glomerular filtration rate performs better at detecting preclinical end-organ changes than alternative equations in black Africans[J].J Hypertens, 2016, 34(6):1178-1185.DOI:10.1097/HJH.0000000000000924.
[21] Diego E, Castro P, Soy D, et al.Predictive performance of glomerular filtration rate estimation equations based on cystatin C versus serum creatinine values in critically ill patients[J].Am J Health Syst Pharm, 2016, 73(4):206-215.DOI:10.2146/ajhp140852.
[22] Ma YC, Zuo L, Chen JH, et al.Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease[J].J Am Soc Nephrol, 2006, 17(10):2937-2944.DOI:10.1681/ASN.2006040368.
[23] Prigent A.Measurement of renal function in clinical practice:principles and limitations[J].J Radiol, 2011, 92(4):274-279.
[24] Li Y, Lee HB, Blaufox MD.Single-sample methods to measure GFR with technetium-99m-DTPA[J].J Nucl Med, 1997, 38(8):1290-1295.
[25] Silkalns GI, Jeck D, Earon J, et al.Simultaneous measurement of glomerular filtration rate and renal plasma flow using plasma disappearance curves[J].J Pediatr, 1973, 83(5):749-757.
[26] Klopper JF, Hauser W, Atkins HL, et al.Evaluation of 99mTc-DTPA for the measurement of glomerular filtration rate[J].J Nucl Med, 1972, 13(1):107-110.
[27] Barbour GL, Crumb CK, Boyd CM, et al.Comparison of inulin, iothalamate, and 99mTc-DTPA for measurement of glomerular filtration rate[J].J Nucl Med, 1976, 17(4):317-320.
[28] Maher FT, Tauxe WN.Renal clearance in man of pharmaceuticals containing radioactive Iodine[J].JAMA, 1969, 207(1):97-104.
[29] Levey AS, Bosch JP, Lewis JB, et al.A more accurate method to estimate glomerular filtration rate from serum creatinine:a new prediction equation.Modification of Diet in Renal Disease Study Group[J].Ann Intern Med, 1999, 130(6):461-470.
[30] Odlind B, Hällgren R, Sohtell M, et al.Is 125I iothalamate an ideal marker for glomerular filtration?[J].Kidney Int, 1985, 27(1):9-16.
[31] Michels WM, Grootendorst DC, Verduijn M, et al.Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size[J].Clin J Am Soc Nephrol, 2010, 5(6):1003-1009.DOI:10.2215/CJN.06870909.
[32] Perrone RD.Means of clinical evaluation of renal disease progression[J].Kidney Int Suppl, 1992, 36:S26-32.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[3]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[4]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[5]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[6]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[7]张宝牛,刘晋华,刘炯,等.Hilson血流灌注指数在肾脏疾病中的应用[J].国际放射医学核医学杂志,2015,39(6):467.[doi:10.3760/cma.j.issn.1673-4114.2015.06.007]
Zhang Baoniu,Liu Jinghua,Liu Jiong,et al.Application of Hilson perfusion index in kidney disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):467.[doi:10.3760/cma.j.issn.1673-4114.2015.06.007]
[8]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[9]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[10]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]